To supplement the development of VEGF/VEGFR inhibitors for HCC therapy, new targets are currently being investigated, such as PD-1/PD-L1 [35, 36], CTLA-4 [37, 38], c-Met [39], TGF [40], PI3K/PTEN/Akt/mTOR [41], and Hedgehog [42] etc. Additionally, dysregulation of many signaling pathways has been linked to HCC development and progression, so researchers have sought to derive novel target genes and drug candidates related to these pathways. Here, PTEN is linked to hepatocellular carcinoma.